Venrock led a $276m Series C round in Element Biosciences, a developer of a new and disruptive DNA sequencing platform, with participation from Janus Henderson Investors, Logos Capital, Meritech Capital Partners, Counterpoint Global (Morgan Stanley), T. Rowe Price, Fidelity Management & Research Company, Foresite Capital, JS Capital Management and RA Capital Advisors. "Element will provide researchers with innovative technology choices and more flexible tools for scientific exploration. We are working to realize our vision of dramatically expanding access to high quality, low cost, easy-to-use genomics tools," Molly He, Element Biosciences CEO.